Most organizations specialize in either frontier AI or frontier biology. CZI's Biohub integrates both to create a tight feedback loop. The AI models identify knowledge gaps, which in turn directs the biology team on what specific data sets to generate next. This flywheel of building bespoke data for model training accelerates discovery much faster than using pre-existing public data.

By open-sourcing its model, Boltz created a feedback loop where the community discovered novel use-cases, like a crude but effective "inference-time search" for antibody prediction. This demonstrates how open access allows external users to find creative applications the original developers hadn't considered.

Open-source initiatives like OpenClaw can surpass well-funded corporate R&D because they leverage a global pool of contributors. This distributed approach uncovers genius in unlikely places, allowing for breakthroughs that siloed internal teams might miss.

Building the first large-scale biological datasets, like the Human Cell Atlas, is a decade-long, expensive slog. However, this foundational work creates tools and knowledge that enable subsequent, larger-scale projects to be completed exponentially faster and cheaper, proving a non-linear path to discovery.

CZI's audacious goal wasn't literal, but a forcing function. When scientists called it impossible, CZI asked "Why?" This revealed the core bottleneck wasn't a lack of therapies, but a lack of shared tools and data. This insight redirected their entire strategy from funding individual grants to building foundational infrastructure for the entire scientific community.

CZI set an audacious goal to cure all disease. When scientists deemed it impossible, CZI's follow-up question, "Why not?" revealed the true bottleneck wasn't funding individual projects, but a systemic lack of shared tools, which then became their core focus.

Fears that universal tools reduce differentiation are misplaced. Instead of just leveling the playing field, open tools like OpenFold raise the entire industry's baseline capability. This shifts competition away from who builds the best foundational model to who can ask the most insightful scientific questions.

The massive Cell-by-Gene atlas began as a simple annotation tool to solve a workflow bottleneck for labs. Its utility drove widespread adoption, which unintentionally created a community-driven, standardized data format that became a foundational resource for the field.

Instead of funding small, incremental research grants, CZI's philanthropic strategy focuses on developing expensive, long-term tools like AI models and imaging platforms. This provides leverage to the entire scientific community, accelerating the pace of the whole field.